On Friday, Shares of Chesapeake Energy Corporation (NYSE:CHK), lost -3.92% to $6.87. The day started out with a lower opening price of $7.09, versus its prior close of $7.15. The company traded with the total volume of 21,640,164 shares, while its average trading volume remained 23,154,700 shares. During the last 5 trades the stock plummeted almost -8.28%, as U.S. oil fell below $40 per barrel on Friday, as traders continued a rout that is likely to hand the futures contract its longest string of successive weekly losses since the bust of 1986.
The march below $40 has been on the horizon for weeks as oil prices plunged in July, fueling a fresh round of anxiety in the industry, said Rusty Braziel, president of Houston-based energy analysts RBN Energy.
Chesapeake Energy Corporation produces oil and natural gas through acquisition, exploration, and development of from underground reservoirs in the United States. It holds interests in natural gas resource plays, counting the Haynesville/Bossier Shales in northwestern Louisiana and East Texas; the Marcellus Shale in the northern Appalachian Basin of West Virginia and Pennsylvania; and the Barnett Shale in the Fort Worth Basin of north-central Texas.
Shares of CVS Health Corp (NYSE:CVS), declined -3.59% to $102.21, during its last trading session.
CVS Health Corp, declared that it has accomplished the acquisition of Omnicare, the leading provider of pharmacy services to long term care facilities, for a total enterprise value of about $12.9 billion.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments. The Pharmacy Services segment offers pharmacy benefit administration services, such as plan design and administration, formulary administration, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network administration services, prescription administration systems, clinical services, disease administration programs, and medical pharmacy administration services.
Finally, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), ended its last trade with -11.32% loss, and closed at $11.32.
AEterna Zentaris Inc, stated financial and operating results as at and for the second quarter ended June 30, 2015.
Second Quarter Financial Highlights
Research and development (“R&D”) costs were $4.5 million for the three-month period ended June 30, 2015 , as contrast to $5.5 million for the same period in 2014. A substantial portion of this decrease is mainly due to the realization of cost savings in connection with the Company’s global resource optimization program in addition to to the weakening, in 2015, of the EUR against the US dollar. The decrease was partly compensated by higher third‑party costs associated with the Company’s ZoptEC Phase 3 trial in endometrial cancer.
Selling expenses were $1.7 million for the three-month period ended June 30, 2015 , as contrast to $0.5 million for the same period in 2014. This enhance is mainly attributable to the Company’s implementation of its sales force and the related promotional activities associated with EstroGel® in the last quarter of 2014. More specifically, about $1.0 million of the Company’s selling expenses represented raised costs associated with the Company’s contracted sales force and in-house sales and marketing staff.
Net finance costs were $7.2 million for the three-month period ended June 30, 2015 , as contrast to net financial income of $3.2 million for the same period in 2014. The enhance in net finance costs of $10.4 million is mainly related to the change in the estimated fair value of the Company’s warrant liability.
Net loss for the three-month period ended June 30, 2015 was $15.1 million or $0.14 per basic and diluted share, as contrast to $5.0 million or $0.09 per basic and diluted share for the same period in 2014. This enhance is predominantly due to higher comparative net finance costs and to higher comparative selling expenses, partially offset by lower comparative R&D costs.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
